Uyanık, T. Et Al. 2011. KRAS mutation status is associated with anti EGFR therapy resistance in metastatic colorectal cancer. EACR Anticancer Agents Research Congress , (Antalya, Turkey), 129.

Uyanık, T., Uyanık, G., Amirfallah, A., ÇALIBAŞI, G., Özcan Keskin, A., Kayacık, N., ... BASKIN, Y.(2011). KRAS mutation status is associated with anti EGFR therapy resistance in metastatic colorectal cancer . EACR Anticancer Agents Research Congress (pp.129). Antalya, Turkey

Uyanık, Tuğçe Et Al. "KRAS mutation status is associated with anti EGFR therapy resistance in metastatic colorectal cancer," EACR Anticancer Agents Research Congress, Antalya, Turkey, 2011

Uyanık, Tuğçe Et Al. "KRAS mutation status is associated with anti EGFR therapy resistance in metastatic colorectal cancer." EACR Anticancer Agents Research Congress , Antalya, Turkey, pp.129, 2011

Uyanık, T. Et Al. (2011) . "KRAS mutation status is associated with anti EGFR therapy resistance in metastatic colorectal cancer." EACR Anticancer Agents Research Congress , Antalya, Turkey, p.129.

@conferencepaper{conferencepaper, author={Tuğçe Uyanık Et Al. }, title={KRAS mutation status is associated with anti EGFR therapy resistance in metastatic colorectal cancer}, congress name={EACR Anticancer Agents Research Congress}, city={Antalya}, country={Turkey}, year={2011}, pages={129} }